A Men’s Vitality Supplement Guide: What Is In This Aisle And What Is Behind It

Eight or nine plants and minerals account for almost every bottle in this category. Two of them have a real human evidence base, three have laboratory chemistry and no trial in men, and the rest sit somewhere in between. Knowing which is which makes every label in the aisle readable in about a minute.

Written for the category. Nothing here is an argument for a particular product, including the one this website sells.

Where the evidence is

The two ingredients with real human trials

Start here, because these two carry most of the weight that this whole aisle borrows.

Tongkat ali (Eurycoma longifolia) is the best-evidenced plant in the category. A 2022 systematic review and meta-analysis pooled clinical trials and found an increase in serum total testosterone across them. The individual studies behind it measured different things: quality of life and sexual well-being in 2012, sexual performance scores in 2014, testosterone in ageing men in 2021, and erectile function alongside a training programme over six months. The amounts were consistent: 100 to 400 mg a day of a standardised extract.

Saw palmetto (Serenoa repens) has the largest evidence base of anything in the aisle and the most disappointing findings. The 2023 Cochrane review concluded at high certainty that it provides little to no benefit for urinary symptoms at the researched dose of 320 mg a day. A 2018 meta-analysis of one specific hexanic extract is friendlier about that preparation. It also does not appear to mask a PSA test, contrary to what almost every page on the subject says.

The lesson those two teach together

Being well studied and being effective are different properties. Saw palmetto has been studied more than anything else here and the best-conducted work found little. Tongkat ali has been studied less and found more. Neither fact transfers to a capsule containing a fraction of the trial amount.

Mechanism without measurement

The three with chemistry and no human trial

Horny goat weed (Epimedium) is the most striking case in the aisle. Its marker compound, icariin, inhibits human PDE5 in a test tube — the same enzyme prescription erectile medicines act on. Structural work on synthetic analogues has found modifications far more potent than icariin itself, which is another way of saying icariin is weak. The erectile improvements were demonstrated in rats. There is no randomised trial of Epimedium or icariin in men at any dose, and a review of Epimedium standardisation describes how variable the raw material is between batches.

Sarsaparilla (Smilax) has steroidal saponins and a body of pharmacology and no clinical trial for desire, stamina or hormone levels at any dose.

Wild yam (Dioscorea) carries diosgenin, which a laboratory can convert into hormones and a human body cannot. The one controlled trial applied a cream for three months and measured no change in any hormone it looked at. The 2022 review covers what diosgenin does do, almost all of it in cells and animals.

Why this matters more here than in other aisles

An ingredient with laboratory chemistry and no human trial is not useless. It is unmeasured, which is a different thing. What is not acceptable is a sales page quoting an enzyme assay as though it were a clinical result, and in this category that happens constantly. When you see a mechanism described in confident detail, ask whether anybody has taken it into a person.

One distinction worth learning

Nettle, and the root-or-leaf question that catches everybody

Nettle appears on most labels in this aisle and on a good number of prostate formulas as well. It is there because of one laboratory finding: lignans that bind to sex hormone binding globulin, which would in theory leave more testosterone unbound.

The lignans in that work came from nettle root. The review of the clinical evidence is titled for the root, and the twelve-month randomised trial used root at 459 mg a day. Root is the researched part of the plant.

Nettle leaf is a different material with a different composition, and it has been trialled for different things: the controlled study that exists was about blood sugar in type 2 diabetes. A label that prints nettle leaf and a page that cites the root literature are not describing the same ingredient, and this is the single most common substitution in the aisle.

What the label says	What to look for	Why it matters
Nettle root extract	An amount, ideally with a standardisation.	This is the researched material. 459 mg a day is the trial figure.
Nettle leaf extract	The same, and a page that cites leaf studies.	Different chemistry. The SHBG work does not apply to it.
Nettle extract, part unstated	Ask, or assume leaf.	Root costs more. An unstated part is rarely the expensive one.
Stinging nettle	Which part, and how much.	A common name that covers both and tells you nothing on its own.

This one distinction eliminates a surprising number of claims across the whole category.

A calculation worth doing

Boron, and the arithmetic hiding in a chelate percentage

Boron appears on many of these labels and is almost always printed in a form that obscures how much is actually present. The row typically reads something like boron amino acid chelate 5% followed by a milligram figure, and the milligram figure describes the chelate rather than the boron.

The arithmetic is simple once you know to do it. Twenty milligrams of a chelate declared at 5% is one milligram of elemental boron. Reviews of boron in human nutrition put ordinary dietary intake in roughly that range, so a row like that supplies about a normal day's worth. An earlier review framed the standing question as whether boron is nutritionally relevant at all in people who eat fruit and vegetables.

The general lesson is bigger than boron. Any ingredient printed as a percentage of something else needs the multiplication done before it can be compared with anything, and labels that print the percentage are being more honest than the ones that print only the compound weight.

The hardest line on a label

Extract ratios, and why 100:1 is not a dose

This is the hardest thing on a label in this aisle to read correctly, and it is where the largest gap between impression and information sits.

A 100:1 extract means a hundred units of raw plant material were reduced to one unit of extract. So 10 mg of a 100:1 extract is, by that arithmetic, derived from 1,000 mg of raw material, and labels frequently print that second figure as a dry-weight equivalent. The arithmetic is correct and the impression it creates is usually wrong.

What a ratio does not tell you is what came out. Extraction depends on the solvent, the temperature, the plant part and the process, and two 100:1 extracts of the same plant can differ several-fold in the compounds that matter. A standardisation — a stated percentage of a named marker compound — is the stronger claim, and it is the one the clinical trials in this aisle used. The tongkat ali trials specified standardised extracts, not ratios.

So a ratio is a description of a process and a standardisation is a description of a product. When a label gives only the first, the honest reading is that the amount is not comparable with any published trial.

Three rules for reading a ratio

Do the multiplication: a 10:1 at 8 mg is 80 mg of dry herb equivalent.
A dry-weight equivalent is not the same measure as a standardised extract dose.
A ratio with no standardisation cannot be compared with a trial amount at all.

What outranks the aisle

What the evidence says actually moves the needle

A guide to this aisle that did not include this section would be incomplete to the point of dishonesty, because the interventions with the strongest evidence in the literature are not sold in bottles.

A 2018 meta-analysis of population-based research on lifestyle factors and sexual dysfunction found the strongest associations with smoking, alcohol consumption and physical inactivity. Controlled sleep-restriction studies have moved testosterone measurably in healthy young men inside a week, which is faster than anything in this aisle has been shown to do.

And the clinical point that outranks all of it: erectile difficulty frequently precedes cardiovascular disease, sometimes by years. The AUA guideline begins with evaluation for that reason. A supplement taken instead of an appointment is the one genuinely harmful use of this entire category.

About this review

Sources for this guide

Twenty-six sources, each confirmed through its own record before it was written down.

Leisegang K, Finelli R, Sikka SC, Panner Selvam MK. Eurycoma longifolia (Jack) Improves Serum Total Testosterone in Men: A Systematic Review and Meta-Analysis of Clinical Trials. Medicina (Kaunas). 2022;58(8):1047. PMID 36013514. https://pubmed.ncbi.nlm.nih.gov/36013514/
Ismail SB, Wan Mohammad WM, George A, et al. Randomized Clinical Trial on the Use of PHYSTA Freeze-Dried Water Extract of Eurycoma longifolia for the Improvement of Quality of Life and Sexual Well-Being in Men. Evid Based Complement Alternat Med. 2012;2012:429268. PMID 23243445. https://pubmed.ncbi.nlm.nih.gov/23243445/
Udani JK, George AA, Musthapa M, et al. Effects of a Proprietary Freeze-Dried Water Extract of Eurycoma longifolia (Physta) and Polygonum minus on Sexual Performance and Well-Being in Men: A Randomized, Double-Blind, Placebo-Controlled Study. Evid Based Complement Alternat Med. 2014;2014:179529. PMID 24550993. https://pubmed.ncbi.nlm.nih.gov/24550993/
Chinnappan SM, George A, Pandey P, et al. Effect of Eurycoma longifolia standardised aqueous root extract-Physta on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study. Food Nutr Res. 2021;65:5647. PMID 34262417. https://pubmed.ncbi.nlm.nih.gov/34262417/
Leitão AE, Vieira MCS, Pelegrini A, et al. A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM). Maturitas. 2021;145:78-85. PMID 33541567. https://pubmed.ncbi.nlm.nih.gov/33541567/
Franco JV, Trivisonno L, Sgarbossa NJ, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023;6(6):CD001423. PMID 37345871. https://pubmed.ncbi.nlm.nih.gov/37345871/
Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049-1065. PMID 29694707. https://pubmed.ncbi.nlm.nih.gov/29694707/
Andriole GL, McCullum-Hill C, Sandhu GS, et al. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013;189(2):486-92. PMID 23253958. https://pubmed.ncbi.nlm.nih.gov/23253958/
Dell'Agli M, Galli GV, Dal Cero E, et al. Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008;71(9):1513-7. PMID 18778098. https://pubmed.ncbi.nlm.nih.gov/18778098/
Chau Y, Li FS, Levsh O, Weng JK. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5. PLoS One. 2019;14(9):e0222803. PMID 31539416. https://pubmed.ncbi.nlm.nih.gov/31539416/
Long H, Jiang J, Xia J, Jiang R. Icariin improves SHR erectile function via inhibiting eNOS uncoupling. Andrologia. 2018;50(9):e13084. PMID 29968380. https://pubmed.ncbi.nlm.nih.gov/29968380/
Yong EL, Wong SP, Shen P, et al. Standardization and evaluation of botanical mixtures: lessons from a traditional Chinese herb, Epimedium, with oestrogenic properties. Novartis Found Symp. 2007;282:173-88. PMID 17913231. https://pubmed.ncbi.nlm.nih.gov/17913231/
Tian LW, Zhang Z, Long HL, Zhang YJ. Steroidal Saponins from the Genus Smilax and Their Biological Activities. Nat Prod Bioprospect. 2017;7(4):283-298. PMID 28646341. https://pubmed.ncbi.nlm.nih.gov/28646341/
Hua S, Zhang Y, Liu J, et al. Ethnomedicine, Phytochemistry and Pharmacology of Smilax glabra: An Important Traditional Chinese Medicine. Am J Chin Med. 2018;46(2):261-297. PMID 29433390. https://pubmed.ncbi.nlm.nih.gov/29433390/
Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001;4(2):144-50. PMID 11428178. https://pubmed.ncbi.nlm.nih.gov/11428178/
Semwal P, Painuli S, Abu-Izneid T, et al. Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives. Oxid Med Cell Longev. 2022;2022:1035441. PMID 35677108. https://pubmed.ncbi.nlm.nih.gov/35677108/
Schöttner M, Gansser D, Spiteller G. Lignans from the roots of Urtica dioica and their metabolites bind to human sex hormone binding globulin (SHBG). Planta Med. 1997;63(6):529-32. PMID 9434605. https://pubmed.ncbi.nlm.nih.gov/9434605/
Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine. 2007;14(7-8):568-79. PMID 17509841. https://pubmed.ncbi.nlm.nih.gov/17509841/
Schneider T, Rübben H. Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo controlled multicenter study after 12 months. Urologe A. 2004;43(3):302-6. PMID 15045190. https://pubmed.ncbi.nlm.nih.gov/15045190/
Kianbakht S, Khalighi-Sigaroodi F, Dabaghian FH. Improved glycemic control in patients with advanced type 2 diabetes mellitus taking Urtica dioica leaf extract: a randomized double-blind placebo-controlled clinical trial. Clin Lab. 2013;59(9-10):1071-6. PMID 24273930. https://pubmed.ncbi.nlm.nih.gov/24273930/
Nielsen FH. Update on human health effects of boron. J Trace Elem Med Biol. 2014;28(4):383-7. PMID 25063690. https://pubmed.ncbi.nlm.nih.gov/25063690/
Nielsen FH. Is boron nutritionally relevant? Nutr Rev. 2008;66(4):183-91. PMID 18366532. https://pubmed.ncbi.nlm.nih.gov/18366532/
Allen MS, Walter EE. Health-Related Lifestyle Factors and Sexual Dysfunction: A Meta-Analysis of Population-Based Research. J Sex Med. 2018;15(4):458-475. PMID 29523476. https://pubmed.ncbi.nlm.nih.gov/29523476/
Smith I, Salazar I, RoyChoudhury A, St-Onge MP. Sleep restriction and testosterone concentrations in young healthy males: randomized controlled studies of acute and chronic short sleep. Sleep Health. 2019;5(6):580-586. PMID 31416797. https://pubmed.ncbi.nlm.nih.gov/31416797/
Durukan E, Jensen CFS, Grundtvig Skaarup K, Fode M. Erectile dysfunction and cardiovascular health. Nat Rev Urol. 2026. PMID 42649386. https://pubmed.ncbi.nlm.nih.gov/42649386/
Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633-641. PMID 29746858. https://pubmed.ncbi.nlm.nih.gov/29746858/

Written and reviewed by the VapoFil Team at Vaepofil

These pages are written from the VapoFil label artwork and the distributor’s own batch paperwork. The panel prints an amount for all seven actives, so beside every one of them this desk prints the amount the published trials used — including the two rows where no human trial exists to print. Corrections go onto the page itself and move the review date forward. Write to contact@Vaepofil.com. Last reviewed September 2026.

Keep reading

More about VapoFil

The choosing methodEight questions, in the order that eliminates the most products fastest. What is in VapoFilThis guide applied to one specific label, row by row. Both guidesThe index, and five sources with nothing to sell you.